Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza

NCT02927431 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Stopped The study was stopped early due to lack of enrollment.

Conditions

Virus Diseases

Interventions

DRUG: Danirixin 15 mg FBE
DRUG: Danirixin 50 mg FBE
DRUG: Placebo
DRUG: Oseltamivir 75 mg

Sponsor

GlaxoSmithKline